Hetero Labs' subsidiary Amarox acquires Spain-based Tarbis Farma

2 January 2019

Hetero Labs, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, today announced that its European subsidiary Amarox has acquired Tarbis Farma, a part of Grupo Ferrer Internacional.

Tarbis Farma comes with a robust product portfolio and an extensive marketing network with well-experienced personnel in retail business across Spain.

The acquisition enables Hetero with a strong front-end marketing presence giving Amarox the required commercial infrastructure, product portfolio, manpower and a seamless entry into the retail, hospital and tender business channels in Spain.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK